Avid Bioservices Inc (CDMO)

[cjgaddy]

I would think they would press release ASCO’13 update(s) on Monday, after the poster presentations this weekend (Sat & Sun)…

ABSTRACT: 8095
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Presenter: Mikhail Shtivelband, MD
Track(s): Lung Cancer
Session Type: General Poster Session
Time & Location: Sat, June 1, 8:00 AM - 11:45 AM CDT, S Hall A2
Abstract Conclusions: This randomized, placebo-controlled Phase II trial demonstrated a positive trend favoring 3mg/kg dosage of bavituximab plus docetaxel in overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). 3mg/kg bavituximab in combination with docetaxel was well tolerated and is the planned dose for Phase III.

ABSTRACT: 567
Phase I clinical trial of bavituximab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).
Presenter: Pavani Chalasani, MD, MPH
Track: Breast Cancer
Session Type: General Poster Session
Time & Location: Sat, June 1, 1:15 PM - 5:00 PM CDT, S Hall A2
Abstract Conclusions: Bavituximab is well tolerated in combination with paclitaxel. Early results show promise in terms of clinical responses with 8 of 10 evaluable patients having clinical benefit. Early biomarker results suggest no effect of therapy on platelet activation but decreases in circulating microparticles is observed.

ABSTRACT: 4054
Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.
Presenter: Shuchi S. Pandya, MD
Track: Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Time & Location: Sun, June 2, 8:00 AM - 11:45 AM CDT, S Hall A2
Abstract Conclusions: In this patient population with extensive disease burdens and limited treatment options, bavituximab plus gemcitabine was well tolerated and demonstrated moderate activity in tumor response and survival.

= = = = = = = = = = =
5-16-13: Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting
• Presentations Include Data From Two Phase II Bavituximab Trials in Second-Line NSCLC and Pancreatic Cancer and a Phase I Bavituximab Trial in HER2-Negative Breast Cancer
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=765427

May31-Jun4: ASCO Annual Mtg. 2013, Chicago (Abstracts DL=Feb5) http://chicago2013.asco.org
...Peregrine Pharm. - ASCO Exhibitor Booth #16107 ("Featured Exhibitor") http://events.jspargo.com/asco13/public/ExhibitorList.aspx?Index=P
...3 Bavi ASCO'13 posters: 2nd-Line NSCLC, Pancreatic, MBC(IST) - Abstracts (FTM): http://tinyurl.com/nvwbbkx